falsefalse

Optimizing Early-Stage NSCLC Management: A Multidisciplinary Perspective - Episode 15

Multidisciplinary Perspectives In the Management of Borderline Resectable Early-Stage NSCLC: A Focus on the Role of Pulmonary Rehabilitation

, , ,

Panelists discuss how PD-L1 expression levels significantly impact treatment decisions in unresectable early-stage non–small cell lung cancer (NSCLC), with consensus that biomarker status should be evaluated before finalizing treatment approaches.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:
    PD-L1 Status in Treatment Decisions for Unresectable Early-Stage NSCLC

    Role of PD-L1 Status in Unresectable Early-Stage Disease

    PD-L1 expression serves as a significant biomarker that guides immunotherapy decisions in unresectable early stage NSCLC. Higher PD-L1 expression levels (≥1%) are associated with improved response to immune checkpoint inhibitors, particularly when combined with standard chemoradiation approaches. The magnitude of benefit from immunotherapy appears to correlate with PD-L1 expression levels.

    Treatment Approach for Unresectable Early-Stage NSCLC with PD-L1 <1%

    For patients with unresectable early-stage NSCLC exhibiting low or negative PD-L1 expression (<1%), the recommended treatment approach includes:

    • Definitive concurrent chemoradiation as the foundation of treatment
    • Consideration of consolidation immunotherapy despite low PD-L1 expression, as some patients may still derive benefit
    • Enrollment in clinical trials investigating novel combination approaches specifically for PD-L1–low populations when available
    • Close monitoring for disease progression with early intervention strategies
    • Careful assessment of patient-specific factors including performance status, comorbidities, and tumor characteristics to guide individualized treatment decisions

    This approach recognizes that while PD-L1 status is important for predicting immunotherapy benefit, other factors including disease burden, patient characteristics, and alternative biomarkers should be considered when making treatment decisions for this challenging patient population.

    x